Full-Time

Vice President

Associate General Counsel, Infectious Disease Franchise

Updated on 9/4/2026

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$309k - $383k/yr

+ Annual Bonus + Equity

New Haven, CT, USA

Hybrid

Hybrid role; onsite 3+ days per week in New Haven, CT (approx. 5-10 days per month).

JD

Category
Legal (1)
Required Skills
Management

Get referred to Invivyd

See people who can refer or advise you

Requirements
  • Have a Juris Doctor (Juris Doctor) from an American Bar Association-accredited law school; be a licensed attorney in at least one U.S. state and in good standing in all states where you are licensed; and have the ability to obtain Connecticut in-house counsel registration
  • A minimum of 10 years of relevant experience with a pharmaceutical/biopharma company providing relevant life sciences advice, counsel and support to pharma/biopharma companies
  • Demonstrated expertise in federal and state laws, regulations, rules and guidance and industry codes and principles impacting pharmaceutical manufacturers, including drug labeling, advertising and promotion, scientific exchange, market access communications, government reimbursement and product liability
  • Demonstrated experience supporting regulatory and commercialization teams including providing legal counsel on Medical, Legal, Regulatory review committees, development and implementation of promotional activities, market access communications, drug labeling, scientific exchange; product launch experience strongly preferred
  • Experience supporting regulatory affairs and drug safety in pharmaceutical development and ongoing obligations
  • Knowledge of enforcement landscape including relevant industry litigation, settlements, and corporate integrity agreement obligations
  • Demonstrated senior leadership and personnel management skills and experience
  • On-site presence at Invivyd’s office in New Haven, CT (minimum 3 days a week onsite)
  • Ability to periodically travel (e.g., attend company off-site meetings; field ride-alongs/program monitoring; attend meetings on behalf of Invivyd, such as conferences/congresses); travel is an essential job function
Responsibilities
  • Providing strategic, operational and tactical legal counsel and business advice related to the development and commercialization of Invivyd’s product(s) and product candidate(s)
  • Advising clients on FDA (and global regulatory authority) regulatory matters and compliance with laws, rules, regulations, guidance and industry standards that arise throughout a product lifecycle, including in the areas of product development, regulatory submissions, advertising and promotion, and drug safety
  • Providing legal counsel on health care laws, including the Federal Anti-Kickback Statute, FDCA, False Claims Act, PhRMA Code, FTC, HIPAA, CAN-SPAM, state laws on physician gifts/meals, Sunshine Act, state price transparency reporting, product liability statutes and related health care legal obligations
  • Providing legal advice, business counsel, material review and creation (e.g., informed consent forms, clinicaltrial.gov postings, FDA correspondence and submissions,) to Clinical, Clinical Operations, Regulatory Affairs, Pharmacovigilance relating to clinical trial programs and drug development
  • Providing legal advice, business counsel and training (building and delivering) to the Marketing team on innovative marketing strategies, activities, programs and trainings, including serving as the Legal representative on the Company committee responsible for the review of advertising and promotional strategies and materials, digital and social media initiatives, and working with clients to develop appropriate and compliant strategies for interacting with healthcare providers and other stakeholders
  • Providing legal advice, business counsel and training (building and delivering) to the Market Access team, including advice on developing and implementing payer strategies, pre-approval information exchange materials, distribution models and materials, patient support programs, HEOR studies and communications
  • Providing legal advice, business counsel and training (building and delivering) to the Medical Affairs team on proactive and reactive communications (i.e., scientific exchange, research planning and support, publications), presentations, engagements and other activities; serving as Legal representative on the Company committee responsible for the review of select scientific exchange
  • Reviewing materials for Corporate Affairs (communications) team, including social media posts
  • Working closely with other Legal and Compliance department colleagues to provide consistent and efficient legal and compliance support to the Company. Supporting the creation, review, updating and training of corporate and healthcare compliance policies, SOPs, rules of engagement, and laws, regulations, guidance and codes
  • Providing and coordinating legal support as a member of cross-functional teams
  • Representing the Legal department on cross-functional initiatives and collaborating with other members of the Legal department on internal initiatives
  • Researching issues and supporting the company in providing a wide range of legal advice to internal clients
  • Managing outside counsel resourcing and budget for complex or nuanced areas of law, regulation or policy
  • Lead or support internal investigations on behalf of Legal; lead or support external investigations or litigation, independently, collaboratively, and/or with outside counsel support, as applicable
  • Potential for management of one or more legal teams (e.g., Contracts) and/or direct reports, in role currently or to be hired
Desired Qualifications
  • Product launch experience strongly preferred
  • Buy and bill experience a plus
  • Litigation experience a plus
  • Experience with digital and social media policies, regulations, guidance and industry practice
  • Ability to be a valued business partner
  • Strong interpersonal, written and verbal communications skills
  • Strong problem-solving and decision-making skills with demonstrated ability to think creatively and devise solutions to challenging problems
  • Proactive in identifying issues, opportunities and solutions for short and long-term success and growth for the business and legal team
  • High-quality and continuous improvement orientation, ensuring staying current with relevant laws, regulations, guidance, policies and codes to mitigate risk and provide solutions
  • Travel readiness beyond essential trips could be included but travel is already listed as essential

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Invivyd

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 PEMGARDA revenue reached $14.3 million, up 21% year over year.
  • Invivyd completed enrollment for DECLARATION and LIBERTY, with data expected late Q3 2026.
  • April 2026 sample-size re-estimation and June upsizing boosted statistical power and credibility.

What critics are saying

  • Invivyd disclosed substantial doubt about going concern in May 2026 without new financing.
  • Nasdaq warned on July 23, 2026 after IVVD stayed below $1.00 for 30 days.
  • If DECLARATION disappoints in Q3 2026, Invivyd loses its only near-term value driver.

What makes Invivyd unique

  • Invivyd owns fast-moving antibody engineering for immune-compromised viral prophylaxis, led by VYD2311.
  • DECLARATION’s upsized 2,400-patient design targets symptomatic COVID with BLA-enabling readout in Q3 2026.
  • Michael Mina joined as CMO, adding credibility in vaccine alternative and public-health positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-2%
Yahoo Finance
May 18th, 2026
Invivyd reports $13.7M Q1 revenue, 22% growth, advances COVID-19 monoclonal antibody trial

Invivyd Inc. reported first-quarter earnings on 14 May, with PEMGARDA net product revenue reaching $13.7 million, up 22% year-on-year. The biopharmaceutical company ended the quarter with $184.2 million in cash, supplemented by approximately $20 million from an at-the-market offering in April. The company posted a net loss of $41.4 million, driven by increased operating expenses related to its DECLARATION Phase 3 clinical trial for VYD2311, a COVID-19 monoclonal antibody candidate. The trial achieved initial full enrollment in March, with top-line data now expected in the third quarter. Invivyd is preparing additional Phase 3 trials and advancing its pipeline beyond COVID-19, including VMS063 for measles and VBY329 for paediatric respiratory syncytial virus prophylaxis.

Yahoo Finance
May 14th, 2026
Invivyd reports 22% YoY PEMGARDA revenue growth amid clinical trial investments

Invivyd Inc reported strong revenue growth in its Q1 2026 earnings call, with monoclonal antibody revenues continuing to grow and PEMGARDA revenue increasing 22% year-over-year compared to Q1 2025. The company accelerated recruitment for its pivotal DECLARATION trial, exceeding internal expectations, though recruitment slowed during a lull in COVID-19 cases. The company confirmed virus neutralisation against the Omicron BA.3.2 variant and is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella and Lyme disease. Invivyd reported significant clinical spending on the DECLARATION trial but expects R&D spending to normalise as the VYD2311 trial concludes. The company strengthened its cash position through additional funding raised in April and received positive feedback from policymakers on increased government affairs activity.

Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.